TY - JOUR
T1 - Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001–2018
T2 - Implications for treatment systems and potential impact on client outcomes
AU - Jones, Nicola R.
AU - Nielsen, Suzanne
AU - Farrell, Michael
AU - Ali, Robert
AU - Gill, Anthony
AU - Larney, Sarah
AU - Degenhardt, Louisa
N1 - Funding Information:
This research article was reviewed by the OATS Aboriginal Advisory Group, including Alan Bennett, Doug James, Kim Sullivan, and Craig Vaughan. Record linkage was conducted by the NSW Ministry of Health and the Centre for Health Record Linkage. The Cause of Death Unit Record File (COD URF) is provided by the Australian Coordinating Registry for the COD URF on behalf of the NSW Registry of Births Deaths and Marriages, NSW Coroner and the National Coronial Information System. The authors wish to acknowledge all data custodians for providing access to the datasets used in this study: This work was supported by the National Institutes of Health (R01 DA144740 PI: Degenhardt). SN and LD are supported by Australian National Health and Medical Research Council Research Fellowships(grant numbers 1163961, 1135991). The National Drug and Alcohol Research Centre is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. The authors wish to thank Tom Murphy, the Data Management Officer, for supporting the production of this paper.
Funding Information:
SL has received untied educational grant funding from Indivior. LD has received untied educational grant funding from Indivior, Mundipharma, Seqirus and Reckitt Benckiser. SN has received untied educational grants from Indivior and Seqirus.
Funding Information:
Ethical approval for this study was provided by the NSW Population and Health Services Research Ethics Committee (2018/HRE0205) and the Aboriginal Health and Medical Research Council Ethics Committee (1400/18).
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Background: There has been much research on the efficacy and effectiveness of opioid agonist treatment (OAT), but less on its implementation and sustainability. A challenge internationally has been recruiting and retaining prescribers. This paper aims to characterise the prescribers in terms of OAT prescribing behaviours. Methods: Retrospective cohort study in New South Wales, Australia. Participants were 2199 OAT prescribers between 1 st August 2001−19th September 2018.We examined trends in initiation and cessation of OAT prescribers. Adjusted hazard ratios were calculated to estimate prescriber retention, adjusting for year of initiation, practice type, client load and treatment prescribed. Results: The rate of prescribers ceasing OAT prescribing has been increasing over time: a prescriber who initiated between 2016−2017 had over four times the risk of cessation compared with one who initiated before 2001, AHR: 4.77; [3.67−6.21]. The highest prescriber cessation rate was in prescribers who had prescribed for shorter time periods. The annual percentage of prescribers who ceased prescribing among those who prescribed for ≤5 years increased from 3% in 2001 to 20 % in 2017. By 2017 more prescribers were discontinuing prescribing than new prescribers were starting. Approximately 87 % (n = 25,167) of OAT clients were under the care of 20 % of OAT prescribers (n = 202); half had been prescribing OAT for 17+ years. Conclusions: OAT prescribing is increasingly concentrated in a small group of mature prescribers, and new prescribers are not being retained. There is a need to identify and respond to the reasons that contribute to newer prescribers to cease prescribing and put in place strategies to increase retention and broaden the base of doctors involved in such prescribing.
AB - Background: There has been much research on the efficacy and effectiveness of opioid agonist treatment (OAT), but less on its implementation and sustainability. A challenge internationally has been recruiting and retaining prescribers. This paper aims to characterise the prescribers in terms of OAT prescribing behaviours. Methods: Retrospective cohort study in New South Wales, Australia. Participants were 2199 OAT prescribers between 1 st August 2001−19th September 2018.We examined trends in initiation and cessation of OAT prescribers. Adjusted hazard ratios were calculated to estimate prescriber retention, adjusting for year of initiation, practice type, client load and treatment prescribed. Results: The rate of prescribers ceasing OAT prescribing has been increasing over time: a prescriber who initiated between 2016−2017 had over four times the risk of cessation compared with one who initiated before 2001, AHR: 4.77; [3.67−6.21]. The highest prescriber cessation rate was in prescribers who had prescribed for shorter time periods. The annual percentage of prescribers who ceased prescribing among those who prescribed for ≤5 years increased from 3% in 2001 to 20 % in 2017. By 2017 more prescribers were discontinuing prescribing than new prescribers were starting. Approximately 87 % (n = 25,167) of OAT clients were under the care of 20 % of OAT prescribers (n = 202); half had been prescribing OAT for 17+ years. Conclusions: OAT prescribing is increasingly concentrated in a small group of mature prescribers, and new prescribers are not being retained. There is a need to identify and respond to the reasons that contribute to newer prescribers to cease prescribing and put in place strategies to increase retention and broaden the base of doctors involved in such prescribing.
KW - Buprenorphine
KW - Methadone
KW - Opioid agonist treatment
KW - Opioid dependence
KW - Prescriber
KW - Retention
UR - http://www.scopus.com/inward/record.url?scp=85098469388&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2020.108464
DO - 10.1016/j.drugalcdep.2020.108464
M3 - Article
C2 - 33360851
AN - SCOPUS:85098469388
SN - 0376-8716
VL - 219
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
M1 - 108464
ER -